clinical trial · NCT07377838
Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
EHL Bio Co., Ltd.·phase3·not yet recruiting·n = 286
Atopic DermatitisADSTEM Inj.Placebo
brief summary
Study of ADSTEM Injection for Patients with Moderate to Severe Subacute and Chronic Atopic Dermatitis
started
Jun 1, 2026
primary completion
Jun 1, 2029
completion
Dec 1, 2029
last updated
Feb 12, 2026
official title
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of ADSTEM Inj. for Moderate to Severe Subacute and Chronic Atopic Dermatitis Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol